<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591028</url>
  </required_header>
  <id_info>
    <org_study_id>20-002747</org_study_id>
    <nct_id>NCT04591028</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients</brief_title>
  <official_title>Indocyanine Green Lymphangiography as a Tool for Improving Lymphadenectomy in Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be looking at the safety and added benefit of using the Indocyanine green dye&#xD;
      (ICG) during surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive ICG fluorescence lymph nodes</measure>
    <time_frame>Approximately 30-90 days after surgery</time_frame>
    <description>Total number of lymph nodes removed after surgery that are positive for ICG fluorescence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease positive lymph nodes</measure>
    <time_frame>Approximately 30-90 days after surgery</time_frame>
    <description>Number of ICG positive lymph nodes that are also positive for disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of lymph nodes removed for each lymphatic station of gastrectomy</measure>
    <time_frame>Approximately 30-90 days after surgery</time_frame>
    <description>Total number of lymph nodes removed for each lymphatic station of gastrectomy with NIR+ICG vs gastrectomy without NIR+ICG</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Injection of Indocyamine Green.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine green</intervention_name>
    <description>A one time injection of IDC prior to the day of scheduled surgery.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 and ≤ 75 years of age.&#xD;
&#xD;
          -  Primary gastric adenocarcinoma of any histological subtype confirmed pathologically by&#xD;
             endoscopic biopsy.&#xD;
&#xD;
          -  Clinical stage tumor T1-4a (cT1-4a), N -/+, M0 at preoperative evaluation according to&#xD;
             the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition.&#xD;
&#xD;
          -  No distant metastasis, no direct invasion of adjacent organs such as pancreas and&#xD;
             spleen in preoperative exams.&#xD;
&#xD;
          -  American Society of Anesthesiology score (ASA) class I, II, or III.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients ≤ 18 and ≥ 75 years of age.&#xD;
&#xD;
          -  History of previous upper abdominal surgery (except laparoscopic cholecystectomy).&#xD;
&#xD;
          -  History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal&#xD;
             dissection.&#xD;
&#xD;
          -  History of allergy to iodine agents.&#xD;
&#xD;
          -  History of other malignant disease within past five years.&#xD;
&#xD;
          -  Emergency surgery due to complication caused by gastric cancer, such as bleeding&#xD;
             obstruction or perforation.&#xD;
&#xD;
          -  Patients intraoperatively/postoperatively confirmed as T4b.&#xD;
&#xD;
          -  Patients intraoperatively confirmed as unable to complete D2 lymph node dissection or&#xD;
             R0 dissection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique F Elli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Enrique F. Elli</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

